Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

Eduardo RamacciottiLeandro B AgatiRoberto Augusto CaffaroGiuliano G VolpianiRenato D LopesAnthony J ComerotaJawed Fareed

Published in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2020)

Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.

Keyphrases

venous thromboembolism
direct oral anticoagulants
pulmonary embolism
atrial fibrillation
machine learning
clinical practice